Motley Fool108d agoneutral
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?Infectious disease could fuel Eli Lilly's next growth phase.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
145last 24h
874last 7d
145● bullish (7d)
96● bearish (7d)
214publishers
GuruFocus.com121d agoneutral
Lilly Targets Vaccines With $3.8 Billion Acquisition PushEli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.
Proactive121d agoneutral
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firmsEli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...
Investor's Business Daily121d agoneutral
Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now?Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
Stocktwits121d agoneutral
LLY Stock Back In Spotlight After Sealing 10th Acquisition This Year – Expands Beyond Obesity With $3.8B Vaccine BetEli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.
Quartz121d agoneutral
Eli Lilly acquires three vaccine developers for $3.8 billionThe deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
Quartz126d agoneutral
Eli Lilly acquires Engage Biologics for up to $202 millionThe deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome
The Wall Street Journal127d agoneutral
SpaceX IPO Could Mint Musk World’s First TrillionaireElon Musk could pass an unthinkable wealth threshold, becoming the world’s first trillionaire, depending on investors’ excitement for SpaceX shares when it goes public. If the company surpasses a valuation of about $1.7 trillion, then Musk’s slightly more than 40% stake, combined with his Tesla shares, would make him the first man with a net worth eclipsing 13 figures. The calculation omits restricted shares that SpaceX has granted to Musk, but which haven’t been earned, though it includes options he could exercise shortly.
Motley Fool131d agobullish
Is Kailera Therapeutics a Buy After Its Sizzling IPO?There's a new challenger to the more established players in the weight-loss drug space.
Investor's Business Daily135d agoneutral
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityAnalysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
Investor's Business Daily140d agoneutral
How This Eli Lilly-Tied IPO Stock Fared In Its First QuarterIPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.
Bloomberg141d agobearish
Eli Lilly Sells $9 Billion of Bonds to Fund Acquisitions(Bloomberg) -- Eli Lilly & Co. sold $9 billion of investment-grade bonds Wednesday — the company’s biggest-ever issuance — as it looks to finance an acquisition spree. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysUS Says Offensive Phase of Iran War Over as Ship Hit in StraitAnthropic Unveils AI Agents to Field Financial Services TasksDOJ Plans Intervention in Trump Supreme Court Carroll AppealTrump Pauses Plan to Guide Ships While Seeking Iran DealThe drugm
MT Newswires141d agobearish
Update: Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions(Updates with the company's response in the fourth paragraph.) Eli Lilly (LLY) is looking to rais